Drugs that treat rare diseases are granted various incentives under the Orphan Drug Act of 1983 if they meet criteria related to the size of the rare disease population (under 200,000 people) that can be effectively treated by the drug in question. The Government Accountability Office (GAO) recently issued a report that finds serious deficiencies with the ways in which the Orphan Drug Act is administered by the FDA.
The Government Accountability Office (GAO) recently issued a report that finds serious deficiencies with the ways in which the Orphan Drug Act is administered by the FDA.
Drugs that treat rare diseases are granted various incentives under the Orphan Drug Act of 1983 if they meet criteria related to the size of the rare disease population (under 200,000 people) that can be effectively treated by the drug in question. Demand for orphan designations has grown since the act came into force, with the number of applications tripling in the last decade alone.
In its review of the FDA’s oversight of orphan drugs, GAO found that, while the FDA generally applies consistent criteria to applications for orphan drugs, the agency does not consistently ensure that all required information—such as elements of the drug’s regulatory history and other orphan designations for the product or for the disease state it is intended to treat—is appropriately recorded and used in the regulatory decision-making process.
In 1 case described in the report, a reviewer did not record any prior orphan drug designations for a specific disease despite the fact that 36 related orphan designations were already approved for the disease state at the time of the review. Furthermore, the FDA does not provide instruction on how to use such information in the evaluation of orphan drug applications.
In addition, while the FDA instructs reviewers to consider independent evidence in verifying population estimates for those affected by specific rare diseases, GAO found that in 23 of 148 review templates, reviewers did not include independent verification of population estimates.
GAO also found that orphan drug approvals were concentrated in 2 areas during the period from 2008 to 2017: hematology (10.8%) and oncology (42.5%). In total, there were just 27 therapeutic areas, with 7 of those areas already having 10 or more approved orphan drugs. Of 351 marketing approvals for orphan drugs during this time period, only 252 were for unique drugs, as many products were approved for more than 1 orphan indication. Some drugs were approved to treat 3 or more orphan indications, with products like bevacizumab (Avastin, which faces an oncoming challenge from biosimilar Mvasi) having 9 orphan indications.
In 2017, Kaiser Health News (KHN), together with NPR, reported that the orphan drug program was being used by drug manufacturers to generate additional profits and protect the markets for medicines that already serve large numbers of patients. According to KHN, blockbuster drugs already on the market, like adalimumab (Humira) and trastuzumab (Herceptin), were granted orphan approvals and extra incentives and exclusivities that effectively block biosimilar competition.
GAO called on the FDA to clarify for its reviewers how to use required information to ensure consistency and quality of orphan designation reviews, particularly as demand for these designations grows.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.